| Nov 7 |
Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results
|
| Nov 7 |
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma
|
| Nov 6 |
Adaptive Biotechnologies Q3 2024 Earnings Preview
|
| Nov 1 |
November 2024's Top US Penny Stocks With Growth Potential
|
| Oct 9 |
Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024
|
| Oct 7 |
Is Teva Pharmaceutical Industries (TEVA) Stock Outpacing Its Medical Peers This Year?
|
| Oct 4 |
Parametric company Adaptive Insurance launches operations
|
| Sep 10 |
Adaptive Biotechnologies Faces Tough Road Despite MRD Segment Growth (Rating Downgrade)
|
| Aug 29 |
Adaptive Announces IVDR Certification for clonoSEQ® in European Union
|
| Aug 22 |
Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
|
